FAAH (Fatty-acid amide hydrolase) is an enzyme and a member of the serine hydrolase family. It is also an integral membrane hydrolase with a single N-terminal transmembrane domain. FAAH is responsible for the degradation of fatty acid amides, including the endocannabinoid anandamide, and for regulating palmitoylethanolamide with anti-inflammatory and analgesic properties. FAAH inhibitors selectively inhibit FAAH by displaying analgesic, anti-inflammatory, anxiolytic, and anti-depressive effects without causing any disruptions in motility, cognition, or body temperature. FAAH inhibitors are in the clinical investigative phases for post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, and others. Jazz Pharmaceuticals, J&J, Autobahn Therapeutics, Astellas Pharma, BMS, Sanofi, Eisai, and Merck (MSD) are major players in the FAAH inhibitors market.
Key Market Developments:
- In May 2021, Autobahn Therapeutics acquired ASP 3652, FAAH inhibitor from Astellas Pharma.
- In Dec 2021, Jazz Pharmaceuticals JZP 150, a FAAH inhibitor received Fast Track designation for post-traumatic stress disorders in the USA.
Drugs under the Pipeline for FAAH Inhibitors:
- JZP150
- JNJ-42165279
- ASP3652
- ASP8477
- CC-97489
- SSR411298
- V158866
- BIA 10 2474
- IW-6118
- URB597
Clinical Activity and Developments of Fatty-acid amide hydrolase (FAAH) Inhibitors:
Currently, there are 10 drug products in the FAAH inhibitors, and all of them are in the clinical development phases.
- In Dec 2021, Jazz Pharmaceuticals initiated enrolment in a phase-II trial for post-traumatic stress disorders in the USA, for JZP 150, a FAAH inhibitor.
- In Oct 2022, Janssen Research & Development completed a phase-II trial in pervasive child development disorders in the USA for JNJ 42165279, a FAAH inhibitor.
|
Molecule Name |
Number of Studies |
|
JZP150 |
13 |
|
JNJ-42165279 |
9 |
|
ASP3652 |
8 |
|
ASP8477 |
2 |
|
CC-97489 |
2 |
|
SSR411298 |
2 |
|
V158866 |
2 |
|
BIA 10 2474 |
1 |
|
IW-6118 |
1 |
|
URB597 |
1 |
Target Indication Analysis of FAAH Inhibitors
FAAH inhibitors are in clinical development phases for mental conditions such as post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, neurological disorders, cancer pain, CNS disorders, inflammation, alcoholism, neuropathic pain, and others.
Regional Analysis of FAAH Inhibitors
FAAH Inhibitors Market
According to the World Health Organization’s report on Mental Disorders, in 2019, 970 million people globally were living with a mental disorder, including 52.4% females and 47.6% males. About 301 million people had anxiety disorders, with the highest percentage in upper middle-income countries in 2019. According to the National Health Interview Survey, there was an overall significant increase in the prevalence of any developmental disability from 16.2% to 17.8%, between 2009 and 2017, and in the USA it was 16.93% among children aged 3-17 years, also the higher prevalence was among children living in rural areas. According to a study, in the USA for post-traumatic stress disorder, the point prevalence ranged from 8% to 56.7%, 1-year prevalence from 2.3% to 9.1%, and lifetime prevalence from 3.4% to 26.9%. With increasing cases of mental CNS and neurological disorders, FAAH inhibitors market is also expected to grow.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
JZP150, JNJ-42165279, ASP3652, ASP8477, CC-97489, and SSR411298 are some of the drugs under the pipeline for FAAH inhibitors.
Jazz Pharmaceuticals, J&J, Autobahn Therapeutics, Astellas Pharma, BMS, Sanofi, Eisai, and Merck (MSD) are some of the major players in the FAAH inhibitors market.
Major indications for FAAH inhibitors are post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, neurological disorders, cancer pain, and CNS disorders.
There are a total of ten molecules in the clinical development phases for FAAH inhibitors.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Jazz Pharmaceuticals
- J&J
- Autobahn Therapeutics
- Astellas Pharma
- BMS
- Sanofi
- Eisai
- Merck (MSD)